Rezolute Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Rezolute şirketinin kazançları yıllık ortalama -24% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.8% oranında arttı.

Anahtar bilgiler

-24.00%

Kazanç büyüme oranı

27.04%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-69.74%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • Feb 16

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Oct 14

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Feb 18

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Key Insights Rezolute's estimated fair value is US$0.87 based on 2 Stage Free Cash Flow to Equity Rezolute's US$1.14...

Analiz Makalesi • Sep 21

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Rezolute fair value estimate is US$2.26 Rezolute is estimated...

Analiz Makalesi • Jul 25

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jan 31

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Sep 15

Rezolute GAAP EPS of -$0.37

Rezolute press release (NASDAQ:RZLT): Q4 GAAP EPS of -$0.37. Cash and cash equivalents totaled $150.4 million as of June 30, 2022.

Analiz Makalesi • May 06

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Jan 12

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

If you want to know who really controls Rezolute, Inc. ( NASDAQ:RZLT ), then you'll have to look at the makeup of its...

Gelir ve Gider Dağılımı

Rezolute nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:RZLT Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 26	-81	27	58
31 Dec 25	-84	26	62
30 Sep 25	-77	21	61
30 Jun 25	-74	19	61
31 Mar 25	-73	18	59
31 Dec 24	-71	17	56
30 Sep 24	-69	16	56
30 Jun 24	-68	15	55
31 Mar 24	-58	14	47
31 Dec 23	-57	14	49
30 Sep 23	-56	14	48
30 Jun 23	-52	13	43
31 Mar 23	-48	12	41
31 Dec 22	-44	11	36
30 Sep 22	-43	10	34
30 Jun 22	-41	10	32
31 Mar 22	-38	9	28
31 Dec 21	-31	9	23
30 Sep 21	-25	9	18
30 Jun 21	-21	8	15
31 Mar 21	-18	7	13
31 Dec 20	-19	6	13
30 Sep 20	-19	5	14
30 Jun 20	-20	6	14
31 Mar 20	-20	6	14
31 Dec 19	-37	7	25
30 Sep 19	-34	7	21
30 Jun 19	-33	7	19
31 Mar 19	-42	7	24
31 Dec 18	-25	8	12
30 Sep 18	-27	8	14
30 Jun 18	-30	9	17
31 Mar 18	-24	10	13
31 Dec 17	-27	9	14
30 Sep 17	-27	9	14
30 Jun 17	-24	8	12
31 Mar 17	-27	6	12
31 Dec 16	-22	5	11
30 Sep 16	-21	5	10
30 Jun 16	-21	5	9
31 Mar 16	-14	5	9
31 Dec 15	-14	5	8
30 Sep 15	-12	5	7

Kaliteli Kazançlar: RZLT şu anda kârlı değil.

Büyüyen Kar Marjı: RZLT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RZLT kârlı değildir ve zararlar son 5 yılda yılda 24% oranında artmıştır.

Büyüme Hızlandırma: RZLT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: RZLT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: RZLT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -69.74% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 23:38
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Rezolute, Inc. 12 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Julian Harrison	BTIG
Edward Nash	Canaccord Genuity
Pete Stavropoulos	Cantor Fitzgerald & Co.

Rezolute Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Recent updates

Price target increased by 9.8% to US$5.63

Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

Price target increased by 9.1% to US$4.50

Rezolute, Inc. Provides Insights from Its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from Its Expanded Access Program in Tumor Hyperinsulinism

Chief Financial Officer recently bought US$80k worth of stock

Rezolute, Inc. Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Price target decreased by 74% to US$4.13

New major risk - Share price stability

Forecast to breakeven in 2028

New minor risk - Profitability

Price target increased by 7.1% to US$15.00

Price target increased by 12% to US$14.89

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Rezolute, Inc., Annual General Meeting, Nov 19, 2025

No longer forecast to breakeven

Rezolute, Inc. Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer, Effective August 18, 2025

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute, Inc. announced that it has received $4.209995 million in funding

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $89.993096 million.

Rezolute, Inc. Announces Positive Recommendation After Independent Interim Analysis of Phase 3 Sunrize Study of Ersodetug in Congenital Hyperinsulinism

Chief Financial Officer recently bought US$58k worth of stock

Rezolute Appoints Erik Harris to Its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute, Inc. Provides Update on Its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

New major risk - Shareholder dilution

Rezolute Receives Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Chief Financial Officer recently bought US$53k worth of stock

New minor risk - Share price stability

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors